Mirum Pharmaceuticals Reports Third-Quarter 2026 Financial Results
Mirum reported third-quarter 2026 financial results and provided a business update. The supplied text also mentions ATEBRIOZ approval and launch and positive Phase 3 results, but ends before giving further details.
Story updates
09:01:17 PM UTC
SquawkNews
Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 mil
09:01:46 PM UTC
SquawkNews
Mirum Pharmaceuticals 3Q Loss $40.8M >MIRM
09:02:45 PM UTC
SquawkNews
Nov 03 (Reuters) - Mirum Pharmaceuticals Q3 operating expenses USD 245.467 million.
09:03:28 PM UTC
SquawkNews
*-- Earnings Flash (MIRM) Mirum Pharmaceuticals, Inc. Reports Q3 Revenue $185.7M, vs.
09:28:08 PM UTC
SquawkNews
04:26 PM EST, 11/03/2026 (MT Newswires) -- Mirum Pharmaceuticals (MIRM) reported a Q3 loss late Tues
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the third quarter 2026 and provided a business update.“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 resu…